Relanium - Relanium is a benzodiazepine derivative tranquilizer. It provides anxiolytic, sedative, anticonvulsant, central muscle relaxant effect. The mechanism of action is associated with increased inhibitory effect of GABA in the CNS. Muscle relaxant effect is also due to the inhibition of spinal reflexes. This medication may cause anticholinergic effects.
Relanium, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, Relanium appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Relanium, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with Relanium do have a transient ataxia at higher doses. Relanium was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.
Indication: Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.
Severe anxiety,Insomnia associated with anxiety,Premedication before anaesthesia,Adjunct in seizures,Muscle spasms,Alcohol withdrawal syndrome,Sedation in minor surgical and medical procedures.